FindTrial
Sign In

Does Desmopressin Reduces Kidney Biopsy Related Bleeding Risk

Desmopressin Reduces Bleeding Risk after Percutaneous Kidney Biopsy : A Randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020653
Enrollment
200
Registered
2019-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N009- Acute nephritic syndrome with unspecified morphologic changes Health Condition 2: N049- Nephrotic syndrome with unspecified morphologic changes Health Condition 3: N019- Rapidly progressive nephritic syndrome with unspecified morphologic changes Health Condition 4: N029- Recurrent and persistent hematuriawith unspecified morphologic changes Health Condition 5: N029- Recurrent and persistent hematuriawith unspecified morphologic changes Health Condition 6: N12- Tubulo-in

Interventions

Intervention1: Desmopressin: Intranasal Desmopressin to be given to intervention group two hour prior to procedure. For patients with less than 50kg, 150mcg (one puff) and for greater than 50 kg, 300m

Sponsors

SGPGI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who will undergo kidney biopsy; irrespective of cause and degree of renal dysfunction or proteinuria or hematuria

Exclusion criteria

Exclusion criteria: Ascites, volume overload, parietal edema. Structural renal disease - Renal calculus disease, hydroureteronephrosis, cystic disease, tumor and CAKUT. Solitary single kidney or unequal kidney size or bilateral small kidneys BMI more than or equal to 25 kg/m2. Patients not able to hold breath. Patients on anticoagulant or anti-platelet drugs. Bleeding or clotting disorders. Coronary artery disease, congestive cardiac failure or volume overload Serum sodium less than 130 mEq/l Kidney transplant recipients Pregnancy and Lactation

Design outcomes

Primary

MeasureTime frame
To evaluate whether desmopressin reduces the bleeding risk and severity after percutaneous kidney biopsy.Timepoint: with in 24 hour of biopsy—

Secondary

MeasureTime frame
1. To evaluate weather administration of desmopressin in uremic patients increases FVIII, von Willebrand factor and platelet function. 2. To study safety profile of intra-nasal desmopressin. Timepoint: 24 hours—

Countries

India

Contacts

Public ContactNarayan Prasad

Sanjay Gandhi Postgraduate Institute of Medical Sciences

narayan@sgpgi.ac.in8004904352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026